Globally, transferring TB patients to another health unit for treatment continuation is common trend while posing challenges for proper treatment outcomes monitoring. National guidelines indicated the importance of incorporating the treatment outcomes of those cases by the transferring unit when performing annual cohort analysis. However, in most instances, this is not taken into account. This study was conducted to determine the characteristics and treatment outcomes of 'transfer out' TB cases during the time period between 2011 and 2015 at four Hospitals of Tigray: Ethiopia. Initial data was extracted from TB treatment logbooks of transferring units using standardize checklist that were followed by a visit to each of the receiving units. The generated data were entered and analyzed using SPSS v. 22.0. Descriptive statistics were computed. P-value less than 0.05 were considered statistically significant. A total of 143 TB patients were transferred out during the specified time period whereas 73.4% (105/143) patients were traced and classified as "arrivals". From these, more than three-quarters, 87.6% (92/105), of patients had a successful treatment outcome (5.7% cured and 81.9% completed treatment) while 13/105 (12.3%) had an unsuccessful outcome (2.8% defaulted, 5.7% died, 1.9% failed, and 1.9% transferred out). However, none of the transferring unit received and traced status of the cases. Therefore, regular monitoring is needed to improve the existing communication gap.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613028PMC
http://dx.doi.org/10.1155/2019/1761694DOI Listing

Publication Analysis

Top Keywords

treatment outcomes
16
characteristics treatment
8
hospitals tigray
8
transferring unit
8
time period
8
treatment
7
patients
5
outcomes
4
outcomes "transfer
4
"transfer out"
4

Similar Publications

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.

Clin Cancer Res

January 2025

United States Food and Drug Administration, Silver Spring, Maryland, United States.

On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.

View Article and Find Full Text PDF

Ischemic stroke is a major cause of adult disability. Early treatment with thrombolytics and/or thrombectomy can significantly improve outcomes; however, following these acute interventions, treatment is limited to rehabilitation therapies. Thus, the identification of therapeutic strategies that can help restore brain function in the post-acute phase remains a major challenge.

View Article and Find Full Text PDF

For the first time, a separate Czech guideline focuses exclusively on hepatitis D virus (HDV) infection. Until recently, HDV infection was only mentioned in guidelines concerning hepatitis B virus (HBV) infection, in chapters on HBV/HDV co-infection. The guideline is based on the July 2023 recommendations from the European Association for the Study of the Liver.

View Article and Find Full Text PDF

[Pneumocystis pneumonia].

Klin Mikrobiol Infekc Lek

September 2023

Clinic of Infectious Diseases, Faculty of Medicine, Masaryk University, University Hospital Brno, Czech Repubic, e-mail:

In parallel with the introduction of modern therapeutic and pharmacological interventions that have successfully resolved many diseases and conditions, previously deemed incompatible with life, there has been a significant increase in the number of patients experiencing secondary immunodeficiency. As a result, these patients are highly susceptible to various opportunistic infections. Among these infections, pneumocystis pneumonia (PCP) stands out as one of the most frequent and potentially life-threatening ones, necessitating prompt diagnosis and treatment.

View Article and Find Full Text PDF

Background: Upfront 2-stent techniques are often used in bifurcation percutaneous coronary interventions (PCI), but there is controversy about optimal strategy selection.

Methods: The authors examined the clinical and angiographic characteristics and long-term outcomes of 232 bifurcation PCIs that were performed using the double kissing (DK) crush or culotte technique in 216 patients between 2014 and 2023 using data from the Prospective Global Registry for the Study of Bifurcation Lesion Interventions (NCT05100992). The inverse probability of treatment weighted (IPTW) Cox proportional hazards model was used to assess long-term outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!